The Association between  the Response to Rituximab with Sociodemographic Data and Disease Characteristics Among a Sample of Iraqi Patients with Rheumatoid Arthritis

Aya Fawzi Talib; Mohammed Mahmood Mohammed

doi:10.54133/ajms.v7i1(Special).914

Authors

Aya Fawzi Talib Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0009-0004-3470-4599
Mohammed Mahmood Mohammed Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0002-1205-4829

DOI:

https://doi.org/10.54133/ajms.v7i1(Special).914

Keywords:

DAS28, Rheumatoid arthritis, Rituximab, Responsiveness

Abstract

Background: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease. Rituximab (RTX), a monoclonal antibody with anti-CD20 action, is now used as a treatment. Even with proper RTX use, some patients showed variations in response. Objective: To assess the association of different sociodemographic data and disease characteristics with RTX responsiveness in RA patients. Methods: A cross-sectional study was conducted in the Specialized Center of Rheumatology at Baghdad Teaching Hospital in Baghdad, Iraq. The study included 90 RA patients who received a 1000mg RTX intravenous infusion for at least six months. The collected sociodemographic data included age, gender, smoking status, body mass index (BMI), disease characteristics such as co-morbidities, and the use of previous biological agents. The activity of RA was assessed by the 28-joint Disease Activity Score (DAS28) and Clinical Disease Activity Index (CDAI). Results: Upon measuring the DAS28, the enrolled patients were divided into RTX responders (50 patients) and RTX non-responders (40 patients). Patients with a family history of RA were significantly higher in the RTX responders (21% versus 2% in the non-responders group). The responders had a significantly longer RA duration (p=0.030).The mean of CDAI and DAS28 were significantly higher in patients with no family history of RA than in those with a family history of RA. Conclusions: Disease duration, family history, and the use of previous biological agents could be considered as possible predictors of response to RTX, thereby saving time and treatment costs.

Downloads

Download data is not yet available.

References

Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nature Commun. 2018;9(1):2755. doi: 10.1038/s41467-018-05044-4,

Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, et al. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies. JAMA Netw Open. 2023;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098.

Brynedal B, Yoosuf N, Ulfarsdottir TB, Ziemek D, Maciejewski M, Folkersen L, et al. Molecular signature of methotrexate response among rheumatoid arthritis patients. Front Med. 2023;10:114635. doi: 10.3389/fmed.2023.1146353.

Shaw Y, Metes ID, Michaud K, Donohue JM, Roberts MS, Levesque MC, et al. Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. Arthritis Care Res (Hoboken). 2018;70(4):533-541. doi: 10.1002/acr.23301.

Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6(1):15. doi: 10.1038/s41413-018-0016-9.

Otón T, Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019;33(5):101477. doi: 10.1016/j.berh.2019.101477.

Thamer W. Study of some immunological effects of methotrexate in people with rheumatoid arthritis. Al-Qadisiyah J Pure Sci. 2019;24(2). doi: 10.29350/jops.2019.24.2.957.

Ball RJ, Avenell A, Aucott L, Hanlon P, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):274. doi: 10.1186/s13075-015-0755-6.

Fatel ECdS, Rosa FT, Dichi I. Adipokines in rheumatoid arthritis. Adv Rheumatol. 2019;58:25. doi: 10.1186/s42358-018-0026-8.

Sepriano A, Kerschbaumer A, Smolen JS, Van Der Heijde D, Dougados M, Van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760-770. doi: 10.1136/annrheumdis-2019-216653.

Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: A review of the literature and practical guide. Drugs Aging. 2019;36(12):1061-1072. doi: 10.1007/s40266-019-00714-4.

Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(3):S2. doi: 10.1186/ar4174.

Mohammed MM, Al-Shamma K, Jasim N. Evaluation of the anti-inflammatory effect of metformin as adjuvant therapy to NSAID (meloxicam) in patients with knee osteoarthritis. Int J Sci Nature. 2014;5:277-282.

Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6(1):e000536. doi: 10.1136/rmdopen-2017-000536.

Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol Ther. 2017;4(2):247-261. doi: 10.1007/s40744-017-0073-3.

Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol. 2021;32(10):2652-2663. doi: 10.1681/ASN.2021040561.

Oldenburg P. Rituximab. Reference Module in Biomedical Sciences: Elsevier; 2018. doi: 10.1016/B978-0-12-801238-3.97945-5.

Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2(2):99-111. doi: 10.1007/s40744-015-0016-9.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR)-European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):782. doi: 10.1136/annrheumdis-2017-211401.

Shrader J, Popovich J, Gracey G, Danoff J. Navicular drop measurement in people with rheumatoid arthritis: Interrater and intrarater reliability. Phys Ther. 2005;85:656-664. doi: 10.1093/ptj/85.7.656.

Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther. 2005;7:1-9.doi:org/10.1186/ar1787.

Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P. Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomed. 2021;92(4):e2021238-e.

Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol-Incl Suppl. 2011;29(6):991.

Karataş A, SaĞIr RP, Koca SS, DalkiliÇ HE, Can G, Pehlivan Y, et al. Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish J Med Sci. 2023;53(5):1321-1329. doi: 10.55730/1300-0144.5698.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012;39(2):240-246. doi: 10.3899/jrheum.110610.

Abdul K, David Lloyd S, Mike B. Smoking, rheumatoid factor status and responses to rituximab. Ann Rheum Dis. 2012;71(9):1587. doi: 10.1136/annrheumdis-2012-201758.

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken). 2013;65(4):648-652. doi: 10.1002/acr.21865.

Tareq Abdulazeez S, Salman S, Gorial FI. Efficacy, Safety and predictors of response to rituximab in treatment of Iraqi patients with active rheumatoid arthritis. Al-Anbar Med J. 2019;15(1):16-21. doi: 10.33091/amj.2019.170886.

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, et al. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol. 2017;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2.

Mohammed TS, Maroof RE, Al-Hafidh AH. Rheumatoid Arthritis effects on kidney and liver and their correlations with CDAI. J Techniques. 2022;4(4). doi: 10.51173/jt.v4i33.698.

Di Muzio C, Cipriani P, Ruscitti P. Rheumatoid arthritis treatment options and type 2 diabetes: Unravelling the association. BioDrugs. 2022;36(6):673-685. doi: 10.1007/s40259-022-00561-7.

Pekdiker M. The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis. Interdiscipl Med J. 2023;14(49):105-110. doi: 10.17944/interdiscip.1351896.

Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: A narrative review. J Clin Med. 2021;10(3). doi: 10.3390/jcm10030509.

Gudelj Gračanin A, Marković I, Golob M, Lucijanić M, Valetić AM, Morović-Vergles J. The effect of smoking on disease activity in rheumatoid arthritis - our experience. Acta Clin Croat. 2020;59(2):312-317. doi: 10.20471/acc.2020.59.02.15.

Miura T, Miyakoshi N, Kashiwagura T, Tsuchie H, Sugimura Y, Shimada Y. The association between comorbidities and disease activity in patients with rheumatoid arthritis: a multicenter, cross-sectional cohort study in Japan with the highest proportion of elderly individuals. Egypt Rheumatol Rehabil. 2022;49(1):7. doi: 10.1186/s43166-021-00109-7.

Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis. 2016;75(6):1120-1125. doi: 10.1136/annrheumdis-2015-207670.

Slama IB, Allali F, Lakhdar T, El Kabbaj S, Medrare L, Ngeuleu A, et al. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2015;16:268. doi: 10.1186/s12891-015-0718-8.